Stifel analyst Bradley Canino initiated coverage of Pyxis Oncology with a Buy rating and $10 price target. The firm sees “a unique oncology investment” into upcoming Phase 1 data for PYX-201 in solid tumors due this fall as its research supports that Pyxis’ first-in-concept “non-internalizing” ADC mechanism has a high likelihood of technical success for shrinking tumors with the bystander effect using the in-licensed Pfizer technology, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
- 3 Best Stocks to Buy Now, 7/29/2024, According to Top Analysts
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pyxis Oncology Appoints Michael Metzger to Board and Committees
- Pyxis Oncology appoints Metzger to board of directors